Feed SRPT
SR

Sarepta Therapeutics SRPT · NASDAQ

$17.10 -3.88% (-$0.69)

Market cap
$1.88B
Enterprise value
$2.35B
P/E
-
Forward P/E
5.5x
PEG
-
P/S
1.0x
P/FCF
-
EV/EBITDA
-
ROIC
-5.6%
Gross margin
58.6%
Net margin
-6.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.21
Free float
95.1%

About the company

Sarepta Therapeutics, Inc. (SRPT) is an American biopharmaceutical company focused on research, development, and commercialization of drugs for the treatment of rare genetic diseases. The company specializes in treating muscular dystrophies caused by genetic mutations. Sarepta Therapeutics develops innovative therapies based on gene therapy and RNA technologies, which have the potential to provide new treatment options for patients with rare genetic diseases. With its successful research programs and collaboration with renowned experts in the field, the company has become a significant player in the field of muscular dystrophy treatment. Shares of Sarepta Therapeutics, Inc. (SRPT) can represent an interesting investment opportunity for those seeking exposure to the biotechnology industry with a focus on treating rare genetic diseases and innovative therapeutic approaches.

Sector

Healthcare

Industry

Biotechnology

CEO

Michael E. Severino

Employees

835

Headquarters

Cambridge

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.